NCT03663374已完成3 期
International Multicentre Randomized Double-blind Placebo Controlled Phase III Clinical Study to Assess Efficacy and Safety of Odelepran, 125 mg, for the Use in Patient With Alcohol Dependence
R-Pharm22 个研究点 分布在 2 个国家目标入组 644 人开始时间: 2014年11月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 644
- 试验地点
- 22
- 主要终点
- Change from baseline in the mean daily alcohol consumption
研究概览
简要总结
The purpose of this study was to assess efficacy and safety of the study drug Odelepran, 125 mg as compared to placebo in the treatment of alcohol dependence in adult outpatients.
详细描述
Patients for this study were recruited in specialized psychiatric and addictology clinical sites in Russia and Kazakhstan. Eligible patients were randomly allocated in one of the following treatment groups in 1:1 ratio:
- The main group was taking the study drug Odelepran, one 125 mg tablet per day;
- The comparison group was taking the comparison drug (Placebo) orally, one tablet per day.
Duration of the study treatment period was 24 weeks (starting from the Day 1). Patients were keeping a diary to register their drug taking and amount and kind of alcohol beverages consumed.
Patients were not allowed to participate in psychotherapy or take any psychotropic drugs except for short-acting benzodiazepines for insomnia. However benzodiazepines were not allowed for taking less than 24 before any study visit.
Patients visited clinical sites regularly as per the Schedule for visits and procedures. During the visits to the site the patient's mental state examination with the use of psychometric scales was conducted and the study drug was provided.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent.
- •Outpatients (not hospitalized by the moment of randomization).
- •Average alcohol consumption during 30 days prior to screening higher than a medium drinking risk level (men: > 4 drinks/day or 14 drinks/week; women > 3 drinks/day or 7 drinks/week) according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria.
- •Patients diagnosed with alcohol dependence according to the International Classification of Diseases (ICD)-10, assessed with the Mini-International Neuropsychiatric Interview (MINI).
- •Abstaining from alcohol during 3 days prior to screening and 3 days before randomization confirmed by the test for alcohol in exhaled air (less than 0,02 %).
- •For women retaining childbearing potential - negative pregnancy test and consent to use reliable contraception methods (as well as for men) throughout the study period, including the study follow up period.
- •Patients able to comply with study protocol as per investigator's opinion.
- •Availability of a patient's trustee who reside with the patient. A trustee is defined here as a person who spends with the patient at least 4 hours a day. The trustee must give his/her consent for participation in the study as the patient's representative.
- •Study drug monotherapy must be acceptable for the patient as per investigator's opinion.
排除标准
- •Hypersensitivity to Odelepran or to any excipient of the study drug (including lactose intolerance).
- •Binge drinking (more than 5 day consecutive days of heavy drinking) during 30 days prior to screening. Heavy drinking is considered as 5 or more drinks per day for men and 4 or more drinks per day for women.
- •Ever diagnosed schizophrenia, schizoaffective disorder, bipolar mood disorder or any other psychiatric disorder, except for alcohol dependence. History of alcohol induced psychosis.
- •Anxiety or depressive disorder present at enrollment into the study. Montgomery-Asberg Depression Rating Scale (MADRS) score higher than
- •High suicidal risk confirmed by MINI.
- •Previous use of opioid antagonists implants less than 3 months prior to screening; use of long-acting naltrexone injections (e,g, Vivitrol) less than 4 weeks after the first injection and 3 months after the second and the following injections; use of cyanamide (Kolme) less than 2 weeks prior to screening, use of oral opioid antagonists or disulfiram during 2 weeks prior to screening.
- •Psychotherapeutic "coding" (a method when the patient is induced a misbelief that alcohol consumption would lead to death, expected to result from undisclosed pharmacological manipulation) that took place during less than 3 months prior to screening.
- •Use of psychotropic medication less than 3 weeks before the screening (for long-acting and 'depot' formulations) or 1 week before the screening (for other formulations) except for those used to treat alcohol withdrawal syndrome.
- •Severe alcohol withdrawal syndrome (severity of alcohol withdrawal more than 10 on Clinical Institute Withdrawal Assessment of Alcohol (CIWA-Ar) scale).
- •History of seizures (excepting febrile seizers). Severe brain injury, history of intracranial neoplasms and/or intracranial haemorrhages or any conditions that impose the risk of seizures. History of anticonvulsive therapy.
- •Any clinical condition affecting cognitive or other psychoneurological functioning (verified for head injury with the loss of consciousness that lasted more than 1 hour, or resulted in cognitive or behavioral impairment, stroke, encephalopathy, dementia, neurodegenerative disorder, etc). Except for mild cognitive impairment.
- •Mental retardation of syndromes of severe organic brain injury.
- •Use of drugs of abuse (opioids, cannabinoids, amphetamines, etc.) or diagnoses of substance addiction/dependence at the moment of screening or positive urine drug screen test.
- •Significant liver function impairment (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) higher than 3 upper limits of normal range or diagnosis of hepatic failure, class B or C by Child Pugh).
- •Severe renal failure (creatinine clearance calculated at the screening less than 30 ml/min or renal replacement therapy).
- •Severe cardiovascular system disorders: unstable angina, poorly controlled arrhythmia, cardiac failure of III or IV class by New-York Heart Association (NYHA), acute myocardial infarction within the past 6 months.
- •HIV-infection, hepatitis B or C.
- •Decompensated diabetes mellitus (determined glycated hemoglobin HbAc1 level more than 7,5%)
- •Other concomitant disorders and conditions that, as per investigator's opinion, put the patient's safety under risk or that could affect the analysis of safety data.
- •Any diagnosed or suspected malignancy.
- •Pregnancy, breast feeding.
- •Participation in any other clinical study during 30 days or 6 periods of half life (depending on what is longer) prior to screening.
- •Patients that need treatment with drugs prohibited by the study protocol (opioid antagonists, psychotropic medications, opioid analgesics, anticonvulsants, central muscle relaxants, antineoplastic drugs, glucocorticoids).
研究组 & 干预措施
Odelepan
Experimental
One tablet once daily
干预措施: Odelepan (Drug)
Placebo
Placebo Comparator
One tablet once daily
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in the mean daily alcohol consumption
时间窗: Baseline and Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 of treatment
Calculated as total number of drinks in month divided by number of days in month.
次要结局
- Proportion of patients completed the trial(Week 24 of treatment)
- Number of the early dropouts from the study(Week 24 of treatment)
- Change in the number of days of abstinence per month as compared to the baseline(Baseline and Week 24 of treatment)
- Change in the percentage of days of heavy drinking per month as compared to the baseline(Baseline and Week 24 of treatment)
- Time to the first day of drinking(From baseline till the first day of alcohol consumption)
- Time to the first day of heavy drinking(From baseline till the first day of heavy drinking)
- Change from baseline in alcohol consumption per drinking day(Baseline and Week Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 of treatment)
- Change in alcohol craving from the baseline (based on Obsessive-Compulsive Drinking Scale (OCDS) score)(Baseline and Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 of treatment)
- Change in alcohol craving (based on completed VIsual Analogue Scale)(Baseline and Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 of treatment)
- Change in patient's self-assessed quality of life (by the SF-36 Questionnaire) as compared to the baseline(Baseline and Week 8, 24 of treatment)
- Proportion of patient with clinical improvement as assessed by Clinical Global Impression-improvement (CGI-I) scale(Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 of treatment)
- Efficacy index of CGI(Week 12 and 24 of treatment)
- Change from baseline in the Drinker Inventory of Consequences questionnaire (DrInC-2R) total score(3 previous months, baseline and Week 4, 8, 12, 16, 20 and 24 of treatment)
- Change in impulsivity (Barratt impulsivity scale by the subscales and by the total score) from the baseline(Baseline and Week 8, 16 and 24 of treatment)
- Time to untimely withdrawal from the study(From baseline to Week 24 of treatment)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative ColitisUlcerative ColitisNCT00033943Incara Pharmaceuticals270
已完成
2 期
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid TherapyOpioid-induced ConstipationNCT01443403Shionogi244
已完成
3 期
Pioglitazone Add-on Study in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00086502Merck Sharp & Dohme LLC353
已完成
3 期
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)Diabetes Mellitus, Type IINCT00086515Merck Sharp & Dohme LLC701
已完成
3 期
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine BleedingMetrorrhagiaNCT00307801Bayer231